CELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of MatTek Corporation ("MatTek"), an American company focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture, to acquire all outstanding shares in MatTek for a purchase price on a cash- and debt-free basis of $68 million (the "Acquisition"). Twenty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash.